Nerve growth factor inhibition with tanezumab influences weight-bearing and subsequent cartilage damage in the rat medial meniscal tear model

作者：LaBranche Timothy P; Bendele Alison M; Omura Brian C; Gropp Kathryn E; Hurst Susan I; Bagi Cedo M; Cummings Thomas R; Grantham Lonnie E II; Shelton David L; Zorbas Mark A

来源：Annals of the Rheumatic Diseases, 2017, 76(1): 295-302.

DOI：10.1136/annrheumdis-2015-208913

<jats:sec><jats:title>Objective</jats:title><jats:p>To investigate whether the effects of nerve growth factor (NGF) inhibition with tanezumab on rats with medial meniscal tear (MMT) effectively model rapidly progressive osteoarthritis (RPOA) observed in clinical trials.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Male Lewis rats underwent MMT surgery and were treated weekly with tanezumab (0.1, 1 or 10 mg/kg), isotype control or vehicle for 7, 14 or 28 days. Gait deficiency was measured to assess weight-bearing on the operated limb. Joint damage was assessed via histopathology. A second arm, delayed onset of treatment (starting 3–8 weeks after MMT surgery) was used to control for analgesia early in the disease process. A third arm, mid-tibial amputation, evaluated the dependency of the model on weight-bearing.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Gait deficiency in untreated rats was present 3–7 days after MMT surgery, with a return to normal weight-bearing by days 14–28. Prophylactic treatment with tanezumab prevented gait deficiency and resulted in more severe cartilage damage. When onset of treatment with tanezumab was delayed to 3–8 weeks after MMT surgery, there was no increase in cartilage damage. Mid-tibial amputation completely prevented cartilage damage in untreated MMT rats.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>These data suggest that analgesia due to NGF inhibition during the acute injury phase is responsible for increased voluntary weight-bearing and subsequent cartilage damage in the rat MMT model. This model failed to replicate the hypotrophic bone response observed in tanezumab-treated patients with RPOA.</jats:p></jats:sec>

• 出版日期2017-1